Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada - Full Text View

Purpose

This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed OH and OAG patients in Canada.

Condition	Intervention
Glaucoma, Open-Angle Ocular Hypertension	Other: There is no intervention in this study.

Genetics Home Reference related topics:

early-onset glaucoma

MedlinePlus related topics:

Glaucoma High Blood Pressure

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Prospective

Official Title:	Distribution of Risk Factors Amongst Ocular Hypertension and Open-Angle Glaucoma Patients in Canada

Further study details as provided by Pfizer:

Primary Outcome Measures:

To describe the presence and distribution of risk factors in subjects diagnosed with OH or OAG stratified according to geographic distribution in a Canadian population in the ophthalmologist practice. [ Time Frame: duration of study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

To describe the severity of disease at the time of diagnosis and to determine if there is a correlation between risk factors, or number of risk factors, and the severity of disease at presentation. [ Time Frame: duration of study ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	400
Study Start Date:	November 2007
Estimated Study Completion Date:	December 2008
Estimated Primary Completion Date:	December 2008 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
There is no intervention in this study This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.	Other: There is no intervention in this study. This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Canadian population

Criteria

Inclusion Criteria:

Subjects diagnosed at study visit or within 3 months of visit with OH
OAG (to include POAG, NTG, pigmentary and pseudoexfoliation glaucoma)

Exclusion Criteria:

No prior treatment for OH or OAG
No prior ocular surgery or history of ocular trauma

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00334750

Contacts


Contact: Pfizer CT.gov Call Center	1-800-718-1021

Locations


Canada, Alberta
	Pfizer Investigational Site	Recruiting
	Calgary, Alberta, Canada, T3E 7M8
	Pfizer Investigational Site	Recruiting
	Edmonton, Alberta, Canada, T5H 0X5
	Pfizer Investigational Site	Recruiting
	Edmonton, Alberta, Canada, T5H 3V9

Canada, British Columbia
	Pfizer Investigational Site	Recruiting
	Nanaimo, British Columbia, Canada, V9R 5B6
	Pfizer Investigational Site	Recruiting
	Vancouver, British Columbia, Canada, V6K 1V7
	Pfizer Investigational Site	Recruiting
	Williams Lake, British Columbia, Canada, V2G 1H1

Canada, Manitoba
	Pfizer Investigational Site	Recruiting
	Winnipeg, Manitoba, Canada, R3C 0N2

Canada, Ontario
	Pfizer Investigational Site	Recruiting
	Brampton, Ontario, Canada, L6V 1B4
	Pfizer Investigational Site	Recruiting
	Mississauga, Ontario, Canada, L5L 1W8
	Pfizer Investigational Site	Recruiting
	Oakville, Ontario, Canada, L6H 3P1
	Pfizer Investigational Site	Recruiting
	Toronto, Ontario, Canada, M4N 3M5
	Pfizer Investigational Site	Recruiting
	Toronto, Ontario, Canada, M5T 2S8
	Pfizer Investigational Site	Recruiting
	London, Ontario, Canada, N6A 4V2
	Pfizer Investigational Site	Recruiting
	Toronto, Ontario, Canada, M5M 1B2
	Pfizer Investigational Site	Recruiting
	Hamilton, Ontario, Canada, L8M 1L6
	Pfizer Investigational Site	Recruiting
	Oakville, Ontario, Canada, L6L 5G8
	Pfizer Investigational Site	Recruiting
	Alliston, Ontario, Canada, L9R 1W7
	Pfizer Investigational Site	Recruiting
	Downsview, Ontario, Canada, M3N 2V6

Canada, Quebec
	Pfizer Investigational Site	Recruiting
	Sherbrooke, Quebec, Canada, J1K 1EB
	Pfizer Investigational Site	Recruiting
	Montreal, Quebec, Canada, H1T 2M4

Canada, Saskatchewan
	Pfizer Investigational Site	Recruiting
	Saskatoon, Saskatchewan, Canada, S7K 3H3

Sponsors and Collaborators

Pfizer

Investigators


Study Director:	Pfizer CT.gov Call Center	Pfizer

More Information

To obtain contact information for a study center near you, click here. This link exits the ClinicalTrials.gov site

Responsible Party:	Pfizer Inc ( Director, Clinical Trial Disclosure Group )
Study ID Numbers:	A6111125
First Received:	June 5, 2006
Last Updated:	September 3, 2008
ClinicalTrials.gov Identifier:	NCT00334750
Health Authority:	Canada: Ethics Review Committee

Keywords provided by Pfizer:

Glaucoma, Open-Angle Ocular Hypertension Risk factors Canadian

Study placed in the following topic categories:

Glaucoma

Eye Diseases

Glaucoma, Open-Angle

Vascular Diseases

Hypertension

Ocular Hypertension

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on October 14, 2008

Sponsored by:	Pfizer
Information provided by:	Pfizer
ClinicalTrials.gov Identifier:	NCT00334750